Syngene International Limited has announced a scheduled virtual meeting with institutional investor OrbiMed Advisors LLC, demonstrating the company's continued engagement with key stakeholders in the investment community.

Meeting Details and Regulatory Compliance

The pharmaceutical services company has formally notified both BSE Limited and the National Stock Exchange of India about the upcoming investor interaction, fulfilling its obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Information Disclosure Guidelines

Syngene International has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the scheduled analyst and investor meeting. This commitment ensures compliance with regulatory frameworks governing information sharing between listed companies and institutional investors.

Corporate Communication Protocol

The notification, dated March 16, 2026, was signed by Chethan Yogesh, Company Secretary and Compliance Officer, and submitted to both major Indian stock exchanges. The company has also confirmed that details of this meeting will be made available on its official website at www.syngeneintl.com , ensuring transparency in corporate communications.

About the Engagement

The virtual meeting format reflects modern corporate practices for investor relations, allowing efficient communication between the Bengaluru-based pharmaceutical services company and international institutional investors. OrbiMed Advisors LLC represents a significant institutional investor in the healthcare and life sciences sector, making this engagement particularly relevant for Syngene International's stakeholder relations.

Syngene International Limited has received a positive development in its tax litigation matters, with the National Faceless Assessment Centre dropping penalty proceedings for Assessment Year 2018-19. The company disclosed this update to stock exchanges on March 14, 2026, in compliance with SEBI Listing Regulations.

Tax Assessment Timeline and Developments

The tax matter originated with an order dated March 27, 2023, when the National Faceless Assessment Centre made a disallowance of expenses worth Rs.2,78,45,669 under sections 147 and 144B of the Income Tax Act for Assessment Year 2018-19. Simultaneously, the authority issued a show cause notice proposing to levy penalty in relation to this disallowance under sections 274 and 270A of the Act.

Successful Appeal Process

Syngene International challenged the initial assessment order before the National Faceless Appeal Centre. The appellate authority passed a favorable order on February 14, 2025, directing the Assessing Officer to verify details and allow relief to the company. Following this directive, the Assessing Officer issued an order on September 11, 2025, giving effect to the appellate order and granting complete relief of Rs.2,78,45,669.

Current Status and Financial Impact

Pursuant to the relief granted, the National Faceless Assessment Centre has now passed an order under section 270A of the Income Tax Act dated March 13, 2026, formally dropping the penalty proceedings that were initiated through the March 27, 2023 notice.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI Listing Regulations, providing comprehensive details of the tax matter resolution. Syngene International stated that no action is required from the company's side since the penalty proceedings have been dropped. The company believes there will be no material impact on its financials, operations, or activities from this development.

This resolution represents a complete closure of the tax litigation matter for Assessment Year 2018-19, with Syngene International successfully defending its position through the appellate process.